CommonHealth lands vet to run patient, interactive

Share this article:
E-marketing veteran Meg Columbia-Walsh has joined WPP-held CommonHealth as managing partner and president.

In her new role, Columbia-Walsh assumes responsibility for CommonHealth's consumer, patient and interactive business, she told MM&M.

“The consumer industry has gone through a lot of change,” said Columbia-Walsh. “We went from being a healthcare-only

discipline to a direct-to-consumer discipline based on the packaged-goods model. Old tactics are not going to work. We really need to harness and build strategic insight into positioning that can be truly articulated into multiple channels. I think that is really the goal moving forward.”

Describing Columbia-Walsh as a force in the industry, CommonHealth CEO Matt Giegerich said, “We're absolutely convinced she will help drive CommonHealth's growth.”

In her 20-year career, Columbia-Walsh has served as managing director of healthcare and technology at Faith Popcorn's Brain Reserve; was partner/VP at Cap Gemini Ernst & Young; founded online healthcare advertising agency HealthTech Digital Communications; founded CBS Healthwatch; and was CEO of Oncology.com.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...